Clinical trial · Observational
Study to Assess Clinical Characteristics and Outcome of Patients with Marginal Zone Lymphomas
Retrospective Observational Study to Assess Clinical Characteristics and Outcome of Patients with Marginal Zone Lymphomas
NCT06806488CI-TRIAL-00085495MarZoLyOssrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a purely retrospective and observational monocentric study
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Marginal Zone B Cell Lymphoma | Marginal Zone Lymphoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- clinical characteristics of Marginal zone lymphoma patients
- timeFrame
- through study completion, an average of 1 years
- description
- to descrive clinical characteristics of Marginal zone lymphoma patients who were diagnosed and treated in our Hospital.
Secondary outcomes (2)
- measure
- effectiveness
- timeFrame
- through study completion, an average of 1 years
- description
- It includes: 1. Description of treatment duration and causes of treatment discontinuation. 2. Description of adverse events / safety of the treatments 3. Assessment of patients' survival. 4. Description of the medical resource utilization, including number of emergency department visits, hospitalizations, use of hematopoietic growth factors and antibiotics, and blood product transfusions. 5. Patient clinical and biological characteristics and disease biological profile at baseline of Marginal zone lymphoma cases
- measure
- safety
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Marginal zone lymphoma patients who were diagnosed and treated in our Hospital between December 2012 and December 2018. 2. Age ≥ 18 years at enrolment. 3. Written informed consent (if applicable) Exclusion Criteria: * none
References
Publications (0)
Data not yet available
No reference posted for this study.